Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
2
MCRB Quote, Financials, Valuation and Earnings
Last price:
$8.56
Seasonality move
:
-13.01%
Day range:
$7.89 - $8.74
52-week range:
$6.53 - $29.98
Dividend yield:
0%
P/E ratio:
14.40x
P/S ratio:
217.13x
P/B ratio:
1.75x
Volume:
63.1K
Avg. volume:
84.6K
1-year change:
-47.34%
Market cap:
$76.5M
Revenue:
--
EPS (TTM):
$0.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MCRB
Seres Therapeutics, Inc.
|
-- | -$1.60 | -100% | -11.49% | $21.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
ALT
Altimmune, Inc.
|
$560 | -$0.24 | -87.6% | -1.45% | $17.67 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835.1M | $0.59 | 11.8% | 33.07% | $88.87 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MCRB
Seres Therapeutics, Inc.
|
$8.74 | $21.00 | $76.5M | 14.40x | $0.00 | 0% | 217.13x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.33 | $31.21 | $4.1B | 15.65x | $0.00 | 0% | 3.91x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$339.37 | $457.00 | $45B | 150.36x | $0.00 | 0% | 12.20x |
|
ALT
Altimmune, Inc.
|
$4.49 | $17.67 | $561.7M | -- | $0.00 | 0% | 17,811.29x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$63.42 | $88.87 | $12.2B | 23.76x | $0.00 | 0% | 4.02x |
|
SVRA
Savara, Inc.
|
$5.72 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MCRB
Seres Therapeutics, Inc.
|
66.11% | 2.472 | 50.61% | 2.16x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
ALT
Altimmune, Inc.
|
7.89% | 0.809 | 4.41% | 16.79x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MCRB
Seres Therapeutics, Inc.
|
-$693K | -$22.5M | 4.41% | 16.36% | -6403.7% | $2.2M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
ALT
Altimmune, Inc.
|
-$22K | -$20.9M | -53.6% | -56.24% | -417180% | -$11.9M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Seres Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns MCRB or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Seres Therapeutics, Inc.'s net margin of 25.76%. Seres Therapeutics, Inc.'s return on equity of 16.36% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital MCRBSeres Therapeutics, Inc.-197.44% $0.94 $129M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About MCRB or ACAD?
Seres Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 140.28%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 28.28%. Given that Seres Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Seres Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MCRBSeres Therapeutics, Inc.1 2 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is MCRB or ACAD More Risky?
Seres Therapeutics, Inc. has a beta of 0.220, which suggesting that the stock is 78.025% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock MCRB or ACAD?
Seres Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MCRB or ACAD?
Seres Therapeutics, Inc. quarterly revenues are $351K, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Seres Therapeutics, Inc.'s net income of $8.2M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Seres Therapeutics, Inc.'s price-to-earnings ratio is 14.40x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics, Inc. is 217.13x versus 3.91x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MCRBSeres Therapeutics, Inc.217.13x 14.40x $351K $8.2M ACADACADIA Pharmaceuticals, Inc.3.91x 15.65x $278.6M $71.8M
-
Which has Higher Returns MCRB or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Seres Therapeutics, Inc.'s net margin of 16.99%. Seres Therapeutics, Inc.'s return on equity of 16.36% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital MCRBSeres Therapeutics, Inc.-197.44% $0.94 $129M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About MCRB or ALNY?
Seres Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 140.28%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 34.66%. Given that Seres Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Seres Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MCRBSeres Therapeutics, Inc.1 2 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is MCRB or ALNY More Risky?
Seres Therapeutics, Inc. has a beta of 0.220, which suggesting that the stock is 78.025% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock MCRB or ALNY?
Seres Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MCRB or ALNY?
Seres Therapeutics, Inc. quarterly revenues are $351K, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Seres Therapeutics, Inc.'s net income of $8.2M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Seres Therapeutics, Inc.'s price-to-earnings ratio is 14.40x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 150.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics, Inc. is 217.13x versus 12.20x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MCRBSeres Therapeutics, Inc.217.13x 14.40x $351K $8.2M ALNYAlnylam Pharmaceuticals, Inc.12.20x 150.36x $1.1B $186.4M
-
Which has Higher Returns MCRB or ALT?
Altimmune, Inc. has a net margin of -- compared to Seres Therapeutics, Inc.'s net margin of -380280%. Seres Therapeutics, Inc.'s return on equity of 16.36% beat Altimmune, Inc.'s return on equity of -56.24%.
Company Gross Margin Earnings Per Share Invested Capital MCRBSeres Therapeutics, Inc.-197.44% $0.94 $129M ALTAltimmune, Inc.-440% -$0.21 $201.5M -
What do Analysts Say About MCRB or ALT?
Seres Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 140.28%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.67 which suggests that it could grow by 296.11%. Given that Altimmune, Inc. has higher upside potential than Seres Therapeutics, Inc., analysts believe Altimmune, Inc. is more attractive than Seres Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MCRBSeres Therapeutics, Inc.1 2 0 ALTAltimmune, Inc.5 1 1 -
Is MCRB or ALT More Risky?
Seres Therapeutics, Inc. has a beta of 0.220, which suggesting that the stock is 78.025% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of 0.091, suggesting its less volatile than the S&P 500 by 90.87%.
-
Which is a Better Dividend Stock MCRB or ALT?
Seres Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MCRB or ALT?
Seres Therapeutics, Inc. quarterly revenues are $351K, which are larger than Altimmune, Inc. quarterly revenues of $5K. Seres Therapeutics, Inc.'s net income of $8.2M is higher than Altimmune, Inc.'s net income of -$19M. Notably, Seres Therapeutics, Inc.'s price-to-earnings ratio is 14.40x while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics, Inc. is 217.13x versus 17,811.29x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MCRBSeres Therapeutics, Inc.217.13x 14.40x $351K $8.2M ALTAltimmune, Inc.17,811.29x -- $5K -$19M
-
Which has Higher Returns MCRB or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Seres Therapeutics, Inc.'s net margin of -3.91%. Seres Therapeutics, Inc.'s return on equity of 16.36% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital MCRBSeres Therapeutics, Inc.-197.44% $0.94 $129M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About MCRB or BMRN?
Seres Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 140.28%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 40.13%. Given that Seres Therapeutics, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Seres Therapeutics, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MCRBSeres Therapeutics, Inc.1 2 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is MCRB or BMRN More Risky?
Seres Therapeutics, Inc. has a beta of 0.220, which suggesting that the stock is 78.025% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock MCRB or BMRN?
Seres Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MCRB or BMRN?
Seres Therapeutics, Inc. quarterly revenues are $351K, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Seres Therapeutics, Inc.'s net income of $8.2M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Seres Therapeutics, Inc.'s price-to-earnings ratio is 14.40x while BioMarin Pharmaceutical, Inc.'s PE ratio is 23.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics, Inc. is 217.13x versus 4.02x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MCRBSeres Therapeutics, Inc.217.13x 14.40x $351K $8.2M BMRNBioMarin Pharmaceutical, Inc.4.02x 23.76x $786.8M -$30.7M
-
Which has Higher Returns MCRB or SVRA?
Savara, Inc. has a net margin of -- compared to Seres Therapeutics, Inc.'s net margin of --. Seres Therapeutics, Inc.'s return on equity of 16.36% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital MCRBSeres Therapeutics, Inc.-197.44% $0.94 $129M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About MCRB or SVRA?
Seres Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 140.28%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 89.03%. Given that Seres Therapeutics, Inc. has higher upside potential than Savara, Inc., analysts believe Seres Therapeutics, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MCRBSeres Therapeutics, Inc.1 2 0 SVRASavara, Inc.6 0 0 -
Is MCRB or SVRA More Risky?
Seres Therapeutics, Inc. has a beta of 0.220, which suggesting that the stock is 78.025% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock MCRB or SVRA?
Seres Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Seres Therapeutics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MCRB or SVRA?
Seres Therapeutics, Inc. quarterly revenues are $351K, which are larger than Savara, Inc. quarterly revenues of --. Seres Therapeutics, Inc.'s net income of $8.2M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Seres Therapeutics, Inc.'s price-to-earnings ratio is 14.40x while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Seres Therapeutics, Inc. is 217.13x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MCRBSeres Therapeutics, Inc.217.13x 14.40x $351K $8.2M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 21.87% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 16.79% over the past day.
